INO: INO-3107 nears FDA decision, backed by strong trial data and commercial launch preparations
A proprietary DNA medicines platform is advancing toward potential approval with INO-3107 for RRP, showing strong efficacy and safety in trials. Commercial readiness is high, with a focused market strategy and robust pipeline, while financials support operations through early 2027.Based on Inovio P…
Story updates
09:12:12 PM UTC
SquawkNews
A proprietary DNA medicines platform is advancing toward potential approval with INO-3107 for RRP, showing strong efficacy and safety in reducing surgeries. Commercial preparations are underway, with a pivotal FDA decision expected October 30 and a robust pipeline and cash runway supporting future…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.